Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

12.51USD
21 Feb 2017
Change (% chg)

$-0.10 (-0.79%)
Prev Close
$12.61
Open
$12.71
Day's High
$12.79
Day's Low
$12.44
Volume
841,745
Avg. Vol
1,895,351
52-wk High
$14.38
52-wk Low
$7.18

Select another date:

Mon, Feb 6 2017

BRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing

* First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing Source text: [http://bit.ly/2kkBxab] Further company coverage:

BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln

* Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses

BRIEF-Halozyme sees FY 2017 revenue $115 mln to $130 mln

* Halozyme provides program updates, 2017 financial guidance at 35th annual JP Morgan healthcare conference

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

BRIEF-Halozyme reports Q3 loss per share $0.23

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Select another date:

More From Around the Web